Dividends & Buybacks ·
Novo Nordisk repurchases DKK 11.2B of shares under ongoing buyback programme
NONOFNovo Nordisk A S
Novo Nordisk has executed additional share repurchases as part of its broader DKK 15 billion programme initiated in February 2026. Since October 19, the company bought approximately 1.2 million B shares for roughly DKK 314 million at prices between DKK 257 and DKK 263 per share. As of late October, total repurchases under the current cycle reached DKK 11.2 billion, representing about 90% of the authorised limit. Novo Nordisk is a global healthcare company developing treatments for diabetes, obesity, and other chronic diseases.